Role of Eotaxin-1 Signaling in Ovarian Cancer

Levina, Vera; Nolen, Brian M.; Marrangoni, Adele; Peng, Cheng; Marks, Jeffrey R.; Szczepański, Mirosław J.; Szajnik, Marta; Gorelik, Elieser; Lokshin, Anna

doi:10.1158/1078-0432.ccr-08-2024

Cited by 85 publications

(68 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, in previous reports, CCL11 increased survival rate of eosinophils, which do not show high proliferation rate (38,39). Moreover, CCL11 induced proliferation of a renal cell carcinoma cell line and an ovarian cell carcinoma cell line (40,41). Taken together, it is likely that we can detect cell survival effects in cells showing little proliferation, whereas growth stimulatory effects can easily be detected in actively proliferating cells.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

CCL11–CCR3 Interactions Promote Survival of Anaplastic Large Cell Lymphoma Cells via ERK1/2 Activation

et al. 2011

View full text Add to dashboard Cite

CCR3 is a specific marker of anaplastic large cell lymphoma (ALCL) cells. ALCL cells also express CCL11, a ligand for CCR3, leading to the hypothesis that CCL11 may play an autocrine role in ALCL progression. In this study, we investigated a role of CCL11 in cell survival and growth of human Ki-JK cells, established from an ALCL patient, and murine EL-4 lymphoma cells. Both Ki-JK and EL-4 cells expressed cell surface CCR3. CCL11 increased cell survival rates of Ki-JK cells in a dose-dependent manner, whereas it promoted EL-4 cell proliferation. Furthermore, CCL11 induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/ 2 in both Ki-JK cells and EL-4 cells. Cell survival and tumor proliferation promoted by CCL11 was completely blocked by inhibition of ERK phosphorylation. CCL11 induced expression of antiapoptotic proteins, Bcl-xL and survivin, in Ki-JK cells. CCL11 also enhanced tumor growth of EL-4 and Ki-JK cells in vivo. Consistent with these results, tumor cells of cutaneous ALCL expressed CCR3 and increased levels of phosphorylated ERK1/2, Bcl-xL, and survivin in situ. Thus, our findings prompt a novel therapeutic approach to treat relapses of an aggressive form of lymphoma based on the discovery that a cell surface marker of disease functions as a critical autocrine growth receptor. Cancer Res; 71(6); 2056-65. Ó2011 AACR.

show abstract

Section: Discussionmentioning

confidence: 57%

“…These results suggest that phosphorylation of ERK1/2 is associated with the cell survival effects of CCL11 in Ki-JK cells. Recently, the same signal pathway was reported to be involved in the growth stimulatory effects of CCL11 on ovarian carcinoma cells (41). EL-4 cells showed phosphorylation of ERK1/2 even without stimulation ( Fig.…”

Section: Discussionmentioning

confidence: 63%

CCL11–CCR3 Interactions Promote Survival of Anaplastic Large Cell Lymphoma Cells via ERK1/2 Activation

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In addition to its role as a chemo-attractant, CCL11 has been implicated in different eosinophilic inflammatory diseases, such as atopic dermatitis, allergic rhinitis, sinusitis, asthma, ulcerative colitis, and in several other gastrointestinal disorders, as well as in parasitic infections [24][25][26][27][28]. Moreover, the levels of serum or plasma CCL11 as diagnostic or prognostic cancer markers have been described in high-grade renal cell carcinomas, high-risk neuroblastoma, as well as in head and neck small cell carcinomas [29][30][31].…”

Section: Discussionmentioning

confidence: 99%

Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer

Kim

Moon

Park

et al. 2016

Urogenit Tract Infect

View full text Add to dashboard Cite

Purpose: CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoattractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) by two research groups. We investigated the usefulness of CCL11 in diagnosing prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa. Materials and Methods: CCL11 was measured in the sera of 139 men with BPH, 44 men with PCa, and 45 control men attending an outpatient health-screening clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure CCL11. Results: CCL11 concentrations were significantly higher in men with BPH and PCa than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and PCa, respectively, compared with normal men. Conclusions: CCL11 may be helpful in diagnosing prostatic diseases, such as BPH and PCa.

show abstract

“…tumor proliferation, migration, and invasion (Levina et al, 2009). Notably, sera from PDAC patients-used as controls in the ovarian cancer study-exhibit significantly elevated levels of CCL11 compared with sera of healthy individuals (Levina et al, 2009).…”

Section: Discussionmentioning

confidence: 99%